Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia | NASH, T2DM, Hyperlipoidemia | Preclinical |
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
CHEK-ATF163 | Human | Human FGF-21 (Luc) HEK293 Reporter Cell | |||
FG1-H82Q3 | Human | Biotinylated Human FGF-21 Protein, His,Avitag™ |
|
||
FG1-H5243 | Human | Human FGF-21 Protein, His Tag |
|
Expression analysis of human Klotho beta on Human FGF-21 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human FGF-21 (Luc) HEK293 Reporter Cell or negative control cell using anti-human Klotho beta antibody followed by staining with PE anti-human IgG antibody.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
BOS-580 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details | |
HEC-88473 | HEC-88473; HEC88473 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity | Details |
YH-25724 | YH-25724; YH25724 | Phase 1 Clinical | Yuhan Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
AP-026 | AP-026; TQA-2226; TQA2226; AP026 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight | Details |
This web search service is supported by Google Inc.